A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
Clinical Trial Grant
Administered By
Neurology, MS & Neuroimmunology
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
September 1, 2015
End Date
October 9, 2017
Administered By
Neurology, MS & Neuroimmunology
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
September 1, 2015
End Date
October 9, 2017